Facebook
Twitter
LinkedIn
ForwardGoing Viral: The Role of Remdesivir in COVID-19 - Online CME Course
Recorded: 01/26/2021
In the past year multiple different medications have been evaluated for use in COVID-19. Remdesivir is an antiviral that showed promise in SARS-CoV-2 infections early in 2020 then was subsequently FDA-approved for its use in COVID-19 in late 2020. This presentation will review the data behind remdesivir’s use and describe an ideal patient population for remdesivir.
See the "Program" tab to view the video. No need to register unless you want to claim credit ($10 fee to claim .50 CME credit hours)
Target Audience
Healthcare workers of all specialties who are being impacted by COVID-19, including physicians, research scientists, physician assistants, nurse practitioners, nurses, and anyone with a particular interest in prevention, treatment, and patient care.
Learning Objectives
Upon completion of this activity you will be able to:
- Describe remdesivir's mechanism of action against SARS-CoV-2
- Identify optimal adult patient populations for remdesivir
- Outline future directions for remdesivir in COVID-19 treatment
Utilization of this Mayo Clinic online (enduring materials) course does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be in this course.
Additional Information
| Attachment | Size |
|---|---|
 Additional Information and Disclosure | 124.78 KB |
You are invited to watch the video at no cost:
To Register and Claim Credit for this segment (.50 hours / $10), follow these steps:
- Select Register Now.
- Complete the checkout process.
- Once you complete your registration, click the “view course page” hyperlink.
- Select the Start button, and then select Start Course button at the bottom of the screen.
- Complete the quiz, fill out the evaluation and claim credit.
If you need additional assistance, contact us or call our toll-free number, 1-800-323-2688.
 | Devyani Lal, M.D. Course Director Associate Dean, Mayo Clinic School of Continuous Professional Development Professor of Otolaryngology, College of Medicine Chair, Division of Rhinology Mayo Clinic in Arizona |
 | Faculty: Jennifer (Jen) L. Adema, Pharm.D., R.Ph. Mayo Clinic School of Health Sciences Pharmacy Resident Mayo Clinic in Minnesota |
Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Statement(s):
AMA
Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ANCC
Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of .50 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
AOA
The American Osteopathic Association designates this program for a maximum of .50 AOA Category 2-A credits.
Other Healthcare Professionals
A record of attendance will be provided to all registrants for requesting credits in accordance with state nursing boards, specialty societies or other professional associations.
For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 AOA Category 2-A
- 0.50 Attendance
Price
Cancellation and Refund Policy
View Cancellation and Refund Policy
All requests must be submitted in writing using the Contact Us Form.
Any use of this site constitutes your agreement to the Terms and Conditions of Registration.